李嶠教授 - 亞洲抗衰老及轉化醫學研究院

李嶠

Professor

Asian Academy of Anti-Aging Research and Translational Medicine（AAAR）

Professional Affiliations

美國密西根大學醫學院

研究教授

Background

李嶠教授，博士畢業于美國密西根州底特律韋恩州立大學生物科學系，現為美國腫瘤協會會員，美國免疫學協會會員，密西根大學醫學院副教授。主要研究方向為腫瘤免疫學和癌症免疫療法。
曾任多家國際雜誌編輯/編委,負責多家國內外雜誌評審，目前為International Journal of Biological Sciences，Chinese Journal of Cancer, Cancer Research，DNA & Cell Biology，Journal for ImmunoTherapy of Cancer，Journal of Translational Medicine等雜誌編委。參與過多屆關於腫瘤免疫和抗癌免疫方面的講座和特邀報告研討會，例如澳門大學的“癌症幹細胞和外泌體 PD-L1 抑制抗腫瘤 B 細胞”。
李嶠教授從事腫瘤免疫學及腫瘤免疫治療研究，在國際著名期刊Cancer Res, Biomaterials, Stem Cells, Oncotarget, Journal of Immunology 等發表80餘篇論文，並參與多本出版書籍章節的編寫。主持包括美國國立衛生研究院（NIH）、INDUSTRIES, FOUNDATIONS IN THE USA,以及《國家高技術研究發展計畫》（863）、《北京市自然科學基金》在內的多個研究項目。
李嶠教授長期從事腫瘤免疫學和免疫治療方面的臨床應用、教學和科研工作，利用具有抗腫瘤活性的免疫T、B淋巴細胞作為細胞藥物治療腫瘤，取得了顯著療效。近年來，他在全球首創靶向ALDHhigh腫瘤幹細胞的DC疫苗，聯合PD-L1抗體，用於鱗狀細胞癌和黑色素瘤的治療，明顯抑制腫瘤生長，減少腫瘤轉移，延長生存期，取得良好療效。其帶領的團隊最早證明靶向腫瘤幹細胞可防止腫瘤復發，2012年美國癌症研究協會(AACR)為其開拓性成果 “腫瘤幹細胞疫苗的抗腫瘤作用”(Cancer Res 2012)召開新聞發佈會。

"轉化醫學的價值在於喚起我們對人性本質的深度思考。我們要超越單純的醫療技術創新,去探索人之為人的內在需求和價值追求,設計出真正服務於生命的療法。"

Li Q, Normolle DP, Sayre DM, Zeng X, Sun R, Jiang G, Redman BD, Chang AE. Immunological effects of BCG as an adjuvant in autologous tumor vaccines. Clin Immunol.2000 Jan;94(1):64-72. doi: 10.1006/clim.1999.4820. PMID: 10607491.
Chang AE, Li Q, Bishop DK, Normolle DP, Redman BD, Nickoloff BJ. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther. 2000 Apr 10;11(6):839-50. doi: 10.1089/10430340050015455. PMID: 10779161.
Li Q,Yu B, Grover AC, Zeng X, Chang AE. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother. 2002 Jul-Aug;25(4):304-13. doi: 10.1097/00002371-200207000-00002. PMID: 12142553.
Chang AE, Li Q, Jiang G, Teknos TN, Chepeha DB, Bradford CR. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer. Head Neck. 2003 Mar;25(3):198-209. doi: 10.1002/hed.10195. PMID: 12599287.
Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol. 2003 Mar 1;21(5):884-90. doi: 10.1200/JCO.2003.08.023. PMID: 12610189.
Ito F, Carr A, Svensson H, Yu J, Chang AE, Li Q.Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother. 2003 May-Jun;26(3):222-33. doi: 10.1097/00002371-200305000-00006. PMID: 12806276.
Li Q,Carr A, Ito F, Teitz-Tennenbaum S, Chang AE. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 2003 May 15;63(10):2546-52. PMID: 12750278.
Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis MA, McGinn CJ, Chang AE. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res. 2003 Dec 1;63(23):8466-75. PMID: 14679011.
Ito F, Li Q,Shreiner AB, Okuyama R, Jure-Kunkel MN, Teitz-Tennenbaum S, Chang AE. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 2004 Nov 15;64(22):8411-9. doi: 10.1158/0008-5472.CAN-04-0590. PMID: 15548712.
Li Q,Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res. 2005 Feb 1;65(3):1063-70. PMID: 15705908.
Li Q,Grover AC, Donald EJ, Carr A, Yu J, Whitfield J, Nelson M, Takeshita N, Chang AE. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J Immunol. 2005 Aug 1;175(3):1424-32. doi: 10.4049/jimmunol.175.3.1424. PMID: 16034078.

李嶠

Professional Affiliations

Background

"轉化醫學的價值在於喚起我們對人性本質的深度思考。我們要超越單純的醫療技術創新,去探索人之為人的內在需求和價值追求,設計出真正服務於生命的療法。"

contact information

Join Us

TikTok

YouTube

Instagram